Natco Pharma, along with its partner Breckenridge Pharmaceutical, has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene in the U.S. market. Pomalidomide capsules, a thalidomide analogue, is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 

It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.

Pomalidomide Capsules, 1mg, 2mg, 3mg and 4mg, had estimated sales of $3.2 billion in the U.S. for 12 months ending September 2025 as per industry sales data. 

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).